Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies

Background: Malignant melanoma is a highly aggressive cancer that spreads and metastasizes quickly. In recent years, the antiangiogenic drug bevacizumab has been trialed to treat malignant melanoma. We conducted the first meta-analysis to examine the efficacy and safety of bevacizumab combined with...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Xiao, Ge, Pu, Liu, Siyu, Yang, Dandan, Zhang, Jinzi, Wang, Xinpei, Liang, Weiting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374288/
https://www.ncbi.nlm.nih.gov/pubmed/37521468
http://dx.doi.org/10.3389/fphar.2023.1163805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374288/
https://www.ncbi.nlm.nih.gov/pubmed/37521468
http://dx.doi.org/10.3389/fphar.2023.1163805

Ejemplares similares